Free lookups: 2/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
2 of 3 free lookups remaining Upgrade
New search Medicine profile Clindamycin

Clinical medicine profile

Clindamycin

Therapeutic agent (verify pharmacological class)

POM
Evidence state General guidance Reviewed 14 Aug 2026
Route
See product SmPC
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
Verification required

This profile needs source confirmation

Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.

01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • Hypersensitivity to the active substance or excipients.
  • Additional absolute contraindications are indication- and product-specific — consult SmPC.

Precautions

  • Obtain allergy and medication history.
  • Adjust for renal/hepatic impairment, pregnancy, lactation, extremes of age and interacting drugs.
  • Use the lowest effective dose for the shortest appropriate duration.
  • Monitor for expected class adverse effects.
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.

Paediatric

Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.

Renal

Review renal impairment dosing; many agents need CrCl/eGFR adjustment.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.

03 Clinical use

Use, effects & interactions

Indications

  • Mild to moderate acne vulgaris
  • minor bacterial skin infections.
  • Clinical selection for Clindamycin (topical) should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
  • Class context: Therapeutic agent (verify pharmacological class).
  • Confirm site-specific dose, duration and monitoring before prescribing.

Adverse effects

  • Adverse reactions vary by agent.
  • Counsel on common predictable effects and serious warning symptoms (allergy, severe rash, jaundice, unusual bleeding, severe GI symptoms, neurological changes).
  • Report suspected ADRs via national pharmacovigilance channels.
  • Professional use: confirm indication, dose, duration, monitoring and patient counselling points against current Kenya STG / EML and the product SmPC.
  • Document allergy status and key interactions.
04 Pharmacology

Mechanism & disposition

Inhibits growth of Propionibacterium acnes.

Inhibits growth of Propionibacterium acnes…Mechanism is agent-specific.At receptor, enzyme, ion channel, transpor…
Read complete mechanism

Inhibits growth of Propionibacterium acnes. Mechanism is agent-specific. At receptor, enzyme, ion channel, transporter or microbial target level, the drug alters a physiological or pathological pathway to produce its therapeutic effect. Confirm precise molecular mechanism in current SmPC / pharmacology reference for this INN before high-stakes decisions.

Onset

Product-specific

Duration

Product-specific

Route

See product SmPC

Elimination

are product-specific. Consider food effects, protein binding, hepatic CYP/UGT

Half-life

when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.

05 Special populations

Pregnancy, lactation & diet

Pregnancy

Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.

Lactation

Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.

06 Kenya market

Brands & loaded prices

FromKES 102
MedianKES 350
Listings13
BrandManufacturerPackObserved price
ClindarGelWallae1% Afya Index / Retail Reference Kenyaliq 5% 5L KES 1,008,000.00afya_index_book
CLINDAZEN 150 ZAIN PHARMA LIMITED Hard Gelatin Capsules Unavailable
CLINDAZEN 300 ZAIN PHARMA LIMITED Hard Gelatin Capsules Unavailable
CLINEP NESHER PHARMA LD Injection Unavailable
DALACIN C DAIMA BIASHARA / Wholesale Import CAPS 300MG 16`s KES 1,869.02daima_biashara_price_list
Dalacin C 150mg Pfizer Laboratories Limited Capsule 150mg Unavailable
Dalacin C 300mg Pfizer Laboratories Limited Capsule 300mg Unavailable
Dalacin C injection Pfizer Laboratories Limited Solution For Injection Unavailable
Monotax? Afya Index / Retail Reference tabs 1's KES 102.00afya_index_book
PIP-OFF GEL Bliss GVS Pharma Ltd. Gel Unavailable
PIP OFF DAIMA BIASHARA / Wholesale Import GEL 25GM KES 322.94daima_biashara_price_list
Powercef Afya Index / Retail Reference tabs 1g 1's KES 350.00afya_index_book
Powercef? Afya Index / Retail Reference tabs 1g 1's KES 350.00afya_index_book
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; Professional class pharmacology (Therapeutic agent (verify pharmacological class))
Last reviewed14 Aug 2026
EvidenceGeneral guidance

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.